Pfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine

Seeking Alpha2022-01-12

Pfizer announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years or older when administered at the same time as the Pfizer-BioNTech COVID-19 Vaccine or when each vaccine was given with placebo.

Responses elicited by PREVNAR 20 for all 20 serotypes were similar whether given with a dose of the COVID-19 Vaccine (n=190) or with placebo (n=191).

Responses to a booster dose of COVID-19 jab were also similar when given with PREVNAR 20 or given with placebo (n=189). The safety profile of co-administering PREVNAR 20 with a booster dose of COVID-19 shot generally reflected that observed with the Pfizer-BioNTech COVID-19 Vaccine booster dose.

Pfizer will seek to present and publish detailed outcomes from this clinical trial at a future date.

On June 8, 2021, FDA approved Pfizer's PREVNAR 20 for the prevention of invasive disease and pneumonia in adults age 18 years or older.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Leave a comment
16